文献速递冠心病外科瓣膜外科

冠脉搭桥联合二尖瓣修复与单纯搭桥治疗中度缺血性二尖瓣反流的成本效果

Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-07-02

基于Cardiothoracic Surgical Trials Network随机试验个体数据,比较冠脉搭桥联合二尖瓣修复(n=150)与单纯搭桥(n=151)治疗中度缺血性二尖瓣反流的成本与质量调整生存。联合修复组住院及2年成本更高,2年QALY差异小,增量成本效果比为$308,343/QALY;10年模型显示成本仍高且QALY无差异,在$100K/QALY阈值下具有成本效果的可能性不超过37%。

要点

  • 联合二尖瓣修复增加住院和2年成本,2年增量成本效果比$308,343/QALY。
  • 10年模型显示联合修复成本更高且QALY无差异,成本效果概率≤37%。
  • 仅当相对降低死亡率5%时,增量成本效果比才低于$100K/QALY。

核心结论

  • 对于中度缺血性二尖瓣反流,在冠脉搭桥基础上加做二尖瓣修复不太可能具有成本效果。
  • 只有当能证明晚期死亡率获益时,才可能满足常用的成本效果标准。

研究设计与样本

  • 基于Cardiothoracic Surgical Trials Network随机试验的个体患者数据,比较冠脉搭桥联合二尖瓣修复(n=150)与单纯搭桥(n=151)。
  • 使用生存、住院、生活质量和美国住院成本数据估算累积成本和质量调整生命年,并建立微模拟模型外推至10年。
  • 采用自举法和确定性敏感性分析处理不确定性。

主要发现

  • 住院成本联合修复组为$59,745,单纯搭桥组为$51,326(差值$8,419;95%不确定性区间2,259-18,757)。
  • 2年成本联合修复组为$81,263,单纯搭桥组为$67,341(差值13,922 [2,370-28,888])。
  • 2年质量调整生命年联合修复组为1.35,单纯搭桥组为1.30(差值0.05;-0.04至0.14),增量成本效果比为$308,343/质量调整生命年。
  • 10年时联合修复组成本仍更高($107,733 vs $88,583,差值19,150 [-3,866至56,826]),质量调整生命年无差异(5.08 vs 5.08)。
  • 基于$100K/质量调整生命年的成本效果阈值,联合修复在10年时被认为具有成本效果的可能性不超过37%。

关键数值与推荐

  • 仅当联合二尖瓣修复相对降低死亡率5%时,增量成本效果比才低于$100K/质量调整生命年。

临床怎么用

  • 在中度缺血性二尖瓣反流患者中,决定是否在冠脉搭桥时加做二尖瓣修复应权衡增加的成本与有限的短期生活质量获益。
  • 若缺乏晚期死亡率获益证据,联合修复可能不符合常用成本效果阈值。

局限性

  • 成本数据基于美国住院成本,外推至10年的结果来自微模拟模型。
  • 原文未报告试验长期随访的死亡率获益数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Cardiothoracic Surgical Trials Network reported that left ventricular reverse remodeling at 2 years did not differ between patients with moderate ischemic mitral regurgitation randomized to coronary artery bypass grafting plus mitral valve repair (n = 150) or coronary artery bypass grafting alone (n = 151). To address health resource use implications, we compared costs and quality-adjusted survival. METHODS: We used individual patient data from the Cardiothoracic Surgical Trials Network trial on survival, hospitalizations, quality of life, and US hospitalization costs to estimate cumulative costs and quality-adjusted life years. A microsimulation model was developed to extrapolate to 10 years. Bootstrap and deterministic sensitivity analyses were performed to address uncertainty. RESULTS: In-hospital costs were $59,745 for coronary artery bypass grafting plus mitral valve repair versus $51,326 for coronary artery bypass grafting alone (difference $8419; 95% uncertainty interval, 2259-18,757). Two-year costs were $81,263 versus $67,341 (difference 13,922 [2370 to 28,888]), and quality-adjusted life years were 1.35 versus 1.30 (difference 0.05; -0.04 to 0.14), resulting in an incremental cost-effectiveness ratio of $308,343/quality-adjusted life year for coronary artery bypass grafting plus mitral valve repair. At 10 years, its costs remained higher ($107,733 vs $88,583, difference 19,150 [-3866 to 56,826]) and quality-adjusted life years showed no difference (-0.92 to 0.87), with 5.08 versus 5.08. The likelihood that coronary artery bypass grafting plus mitral valve repair would be considered cost-effective at 10 years based on a cost-effectiveness threshold of $100K/quality-adjusted life year did not exceed 37%. Only when this procedure reduces the death rate by a relative 5% will the incremental cost-effectiveness ratio fall below $100K/quality-adjusted life year. CONCLUSIONS: The addition of mitral valve repair to coronary artery bypass grafting for patients with moderate ischemic mitral regurgitation is unlikely to be cost-effective. Only if late mortality benefits can be demonstrated will it meet commonly used cost-effectiveness criteria.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ferket BS, Thourani VH, Voisine P, et al. Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2019. PMID: 31375378. doi:10.1016/j.jtcvs.2019.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。